×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
ON DEMAND - Considerations for Long-Term Outcomes Data Collection for Value-Based Payment Arrangements
Session Chair(s)
Monika Schneider, PhD
Director, Global Antimicrobial Resistance Policy
Shionogi Inc., United States
Reimbursement of drugs through value-based payment may benefit from patient data that is not available through clinical trials. This session will explore how early-stage evidence generation might bridge clinical endpoints and clinical endpoints.
Learning Objective : Identify long-term patient outcomes that would benefit from additional early-stage data; Describe the impact of misalignment in clinical validity and clinical utility on evaluation of outcomes in value-based reimbursement; Discuss approaches to incorporate clinical utility measures into the regulatory process, with Alzheimer’s disease as a case study.
Speaker(s)
Payer Perspective
Lisa Mostovoy, PharmD
Blue Cross Blue Shield Association, United States
Executive Director of Clinical Pharmacy Services
Industry Perspective
Phyllis Barkman Ferrell, MBA
Eli Lilly and Company, United States
Global Head, External Engagement, Alzheimer's Disease and Neurodegeneration
Public Payer Perspective
Shari M. Ling, MD
Centers for Medicare an Medicaid Services, United States
Acting Chief Medical Officer
Have an account?